$150,000 of CORMEDIX INC. lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"H.R. 2172/S. 1058, Preserving Patient Access to Home Infusion Act H.R. 6214/S. 2730, Kidney Care Access Protection Act"
You can find more data on corporate lobbying on Quiver Quantitative.
CRMD Insider Trading Activity
CRMD insiders have traded $CRMD stock on the open market 15 times in the past 6 months. Of those trades, 1 have been purchases and 14 have been sales.
Here’s a breakdown of recent trading of $CRMD stock by insiders over the last 6 months:
- JANET DILLIONE has made 0 purchases and 5 sales selling 147,000 shares for an estimated $1,547,555.
- JOSEPH TODISCO (Chief Executive Officer) has made 0 purchases and 2 sales selling 80,000 shares for an estimated $1,010,000.
- ELIZABETH HURLBURT (Chief Operating Officer) has made 0 purchases and 2 sales selling 53,997 shares for an estimated $711,817.
- KAUFMAN BETH ZELNICK (Chief Legal Officer) has made 0 purchases and 2 sales selling 50,000 shares for an estimated $670,264.
- STEVEN W LEFKOWITZ sold 40,000 shares for an estimated $475,200
- ALAN W DUNTON has made 0 purchases and 2 sales selling 30,000 shares for an estimated $391,300.
- MYRON KAPLAN purchased 25,000 shares for an estimated $275,500
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CRMD Hedge Fund Activity
We have seen 144 institutional investors add shares of CRMD stock to their portfolio, and 71 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEERFIELD MANAGEMENT COMPANY, L.P. added 3,323,833 shares (+inf%) to their portfolio in Q3 2025, for an estimated $38,656,177
- MARSHALL WACE, LLP added 893,518 shares (+34.6%) to their portfolio in Q3 2025, for an estimated $10,391,614
- JUMP FINANCIAL, LLC added 774,083 shares (+inf%) to their portfolio in Q3 2025, for an estimated $9,002,585
- NUVEEN, LLC removed 772,997 shares (-52.6%) from their portfolio in Q3 2025, for an estimated $8,989,955
- GHISALLO CAPITAL MANAGEMENT LLC removed 750,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $8,722,500
- ANSON FUNDS MANAGEMENT LP removed 725,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $8,431,750
- RAYMOND JAMES FINANCIAL INC added 564,688 shares (+646.8%) to their portfolio in Q3 2025, for an estimated $6,567,321
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CRMD Analyst Ratings
Wall Street analysts have issued reports on $CRMD in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 01/23/2026
- Needham issued a "Buy" rating on 01/08/2026
- D. Boral Capital issued a "Buy" rating on 12/18/2025
- RBC Capital issued a "Outperform" rating on 10/21/2025
- JMP Securities issued a "Market Outperform" rating on 09/09/2025
To track analyst ratings and price targets for CRMD, check out Quiver Quantitative's $CRMD forecast page.
CRMD Price Targets
Multiple analysts have issued price targets for $CRMD recently. We have seen 5 analysts offer price targets for $CRMD in the last 6 months, with a median target of $14.0.
Here are some recent targets:
- Brandon Folkes from HC Wainwright & Co. set a target price of $13.0 on 01/23/2026
- Leonid Timashev from RBC Capital set a target price of $13.0 on 01/21/2026
- Jason Kolbert from D. Boral Capital set a target price of $14.0 on 01/08/2026
- Serge Belanger from Needham set a target price of $15.0 on 01/08/2026
- Jason N. Butler from JMP Securities set a target price of $22.0 on 09/09/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
